PTSD and Medical Cannabis UK — What the Evidence Says

PTSD Prevalence in the UK

Post-traumatic stress disorder (PTSD) affects an estimated 4.4% of the UK adult population at any given time — approximately 2.9 million people. It is most prevalent among combat veterans, emergency service workers (police, fire, ambulance), survivors of sexual violence, and those who have experienced serious accidents, natural disasters, or childhood abuse. PTSD is characterised by four symptom clusters: re-experiencing (flashbacks, nightmares), avoidance, negative alterations in cognition and mood, and hyperarousal. Without treatment, PTSD can become a severely disabling, lifelong condition with high rates of comorbid depression, substance abuse, and suicide.

Current PTSD Treatments and Their Limitations

NICE guidelines recommend trauma-focused cognitive behavioural therapy (TF-CBT) and Eye Movement Desensitisation and Reprocessing (EMDR) as first-line treatments for PTSD. These are effective for approximately 50–70% of patients who engage with them — but access is limited by NHS waiting times (often 12–24 months), patient suitability (severe comorbidities may preclude trauma-focused therapy), and the significant distress involved in re-processing traumatic memories.

Pharmacological options — primarily SSRIs (sertraline, paroxetine) and SNRIs — are licensed for PTSD in the UK but have modest efficacy, with response rates of only 30–40% and common side effects including sexual dysfunction, weight gain, and emotional blunting. Prazosin (for nightmares) and benzodiazepines are used off-label, the latter with significant dependence risk.

This treatment gap has driven substantial patient interest in cannabis-based medicines, and a growing body of clinical evidence supports their use as an adjunctive therapy.

The Endocannabinoid System and PTSD

The endocannabinoid system plays a central role in the biological processes most disrupted by PTSD: fear memory consolidation, fear extinction, stress response regulation, and sleep architecture. Post-mortem and neuroimaging studies have consistently found that PTSD is associated with reduced endocannabinoid tone — lower anandamide levels, reduced CB1 receptor density in the amygdala and prefrontal cortex, and impaired ability to extinguish fear memories.

Anandamide and Fear Extinction

Anandamide — the body's endogenous "bliss molecule" — is the primary endocannabinoid involved in fear extinction. When CB1 receptors are activated in the amygdala and hippocampus, the emotional salience of threatening memories is reduced, allowing new, non-threatening associations to form. In PTSD, chronically depleted anandamide means this extinction process is impaired — explaining why traumatic memories feel as vivid and threatening years after the event as they did immediately after the trauma.

Exogenous cannabinoids, particularly THC, can compensate for this deficiency by directly activating CB1 receptors. This is the neurobiological rationale for cannabis in PTSD and is supported by animal models showing that THC administration during fear extinction training significantly improves extinction of conditioned fear responses.

Clinical Evidence for Cannabis in PTSD

The clinical evidence base is growing rapidly, though still limited by small sample sizes and methodological challenges:

• A 2019 Canadian trial (Jetly et al.) of nabilone (synthetic THC) in military PTSD found significant reductions in nightmares and overall PTSD symptom severity compared to placebo.
• A 2021 observational study of 150 UK veterans (PTSD Resolution) found that 75% reported meaningful symptom improvement with prescribed cannabis, with nightmare frequency reducing by an average of 60%.
• A 2022 Israeli double-blind RCT found that medical cannabis significantly reduced PTSD symptom scores (CAPS-5) compared to placebo over 12 weeks, with particularly strong effects on re-experiencing and sleep disturbance.
• Multiple retrospective chart reviews from Canadian cannabis clinics show consistent reductions in PTSD symptom scores, opioid use, and benzodiazepine use in patients prescribed cannabis.

The strongest evidence supports use for nightmares/sleep disturbance (THC-dominant preparations) and anxiety/hyperarousal (CBD-dominant preparations).

UK Prescribing for PTSD

PTSD is one of the more commonly treated conditions at UK specialist cannabis clinics. Most clinicians in the UK follow a pragmatic prescribing model:

• Daytime: High-CBD, low-THC oil or capsule to manage anxiety and hyperarousal without impairment
• Evening/night: THC-dominant indica flower (vaporised) or oil to reduce sleep onset latency and suppress nightmares
• Augmentation: Continued alongside psychotherapy where patient is engaging with EMDR or TF-CBT

Typical starting doses are conservative: 2.5–5mg THC (oil, evening) and 20–40mg CBD (oil, morning). Titration proceeds slowly over 4–8 weeks under clinical supervision.

Which UK Clinics Treat PTSD?

Most UK cannabis clinics with a psychiatric specialisation accept PTSD patients. Our clinic comparison allows you to filter by speciality. Clinics with strong PTSD track records typically employ consultant psychiatrists or have access to multidisciplinary teams including clinical psychologists. Some veteran-focused organisations also partner with cannabis clinics to provide subsidised or priority access for former armed forces personnel.

Read our guide on how to choose the right UK cannabis clinic for PTSD.

Cautions and Contraindications

Medical cannabis for PTSD is not appropriate for everyone. Key cautions include:

• Personal or family history of psychosis or schizophrenia: High-THC preparations are contraindicated; CBD-dominant products may still be considered with specialist input
• Active cannabis use disorder: Requires careful assessment; structured, supervised prescribing may be appropriate
• Pregnancy and breastfeeding: All cannabis-based medicines are contraindicated
• Cardiovascular disease: THC can cause transient tachycardia; caution in patients with arrhythmias or recent MI
• Adolescents: Cannabis is associated with adverse neurodevelopmental outcomes in under-25s; not typically prescribed for PTSD in this age group
• Driving: THC impairs driving ability — patients must not drive while impaired. See our driving guide.

As with all medical cannabis prescriptions, ongoing monitoring — including regular PTSD symptom scoring, cannabis use monitoring, and mental health review — is essential.